Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer

Eric S Schaefer,1 Christina Baik2 1Section of Medical Oncology, Highlands Oncology Group, Fayetteville, AR, 2Department of Medicine, Medical Oncology Division, University of Washington School of Medicine, Seattle, WA, USA Abstract: Anaplastic lymphoma kinase (ALK) gene fusions occur in 3%&ndash...

Full description

Bibliographic Details
Main Authors:	Schaefer ES, Baik C
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-03-01
Series:	Cancer Management and Research
Subjects:	case studies ceritinib non-small cell lung cancer gastrointestinal adverse events
Online Access:	https://www.dovepress.com/proactive-management-strategies-for-potential-gastrointestinal-adverse-peer-reviewed-article-CMAR

Similar Items

Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib
by: Taizou Hirano, et al.
Published: (2018-10-01)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016-05-01)

Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer
by: K. K. Laktionov, et al.
Published: (2019-06-01)

Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer
by: Yuke TIAN, et al.
Published: (2020-08-01)

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib
by: Yuki Matsumura, et al.
Published: (2021-08-01)

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
by: Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, et al.
Published: (2021-03-01)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
by: Tung Hoang, et al.
Published: (2020-02-01)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
by: Olaf Beck, et al.
Published: (2020-03-01)

Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway
by: Chen H, et al.
Published: (2018-11-01)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-07-01)

Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report
by: Zhongxing Bing, et al.
Published: (2021-07-01)

Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database
by: Haruka Fujita, et al.
Published: (2020-05-01)

Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
by: Thai Hoa Thi Nguyen, et al.
Published: (2021-07-01)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01)

CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
by: N. V. Mitiushkina, et al.
Published: (2020-09-01)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
by: Herbert H. Loong, et al.
Published: (2020-11-01)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
by: Liu M, et al.
Published: (2019-10-01)

Development And Validation Of Stability Indicating RP-HPLC Method For Determination Of Ceritinib
by: Vaibhav Suresh Adhao, et al.
Published: (2017-10-01)

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
by: Shih‐Hao Huang, et al.
Published: (2019-12-01)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
by: Ryohei Katayama, et al.
Published: (2016-01-01)

Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor
by: Alexandra Russo, et al.
Published: (2019-08-01)

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
by: Chih-Hsi Scott Kuo, et al.
Published: (2021-03-01)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
by: Hou H, et al.
Published: (2019-05-01)

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
by: Kitadai R, et al.
Published: (2018-12-01)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
by: Alfredo Addeo, et al.
Published: (2018-07-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
by: Ken Koshikawa, et al.
Published: (2020-06-01)

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer
by: Cheng-Hao Chuang, et al.
Published: (2021-04-01)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
by: Qian Zhu, et al.
Published: (2017-06-01)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
by: Jain RK, et al.
Published: (2017-10-01)

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
by: Passaro A, et al.
Published: (2016-10-01)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
by: Valerio Gristina, et al.
Published: (2020-12-01)

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
by: David König, et al.
Published: (2020-06-01)

Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo
by: Li Yang, et al.
Published: (2018-05-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

Fabrication of ceritinib cocrystals with improved solubility: Preparation, solid-state characterization, solubility studies, and molecular docking studies
by: Awasthi, A., et al.
Published: (2021)

Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
by: Keiichi Otsuka, et al.
Published: (2018-10-01)

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
by: Amin, Amit Dipak, et al.
Published: (2016)

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
by: Sabari JK, et al.
Published: (2017-04-01)

Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database
by: Riko Satake, et al.
Published: (2021-07-01)

Study of adverse drug reactions in out-patient departments of a teaching hospital
by: Zinnat Ara Begum, et al.
Published: (2012-06-01)

Cannot write session to /tmp/vufind_sessions/sess_tau1gh6qroghqfhmmd2tf8dssk